EVEROLIMUS | N022334 | NOVARTIS PHARMACEUTICALS CORP
| Trial # | Patent | Type | Petitioner | Status | Filed | Decision |
|---|---|---|---|---|---|---|
| IPR2018-00507 | 8410131 | IPR | Hikma Pharmaceuticals PLC | Terminated-Settled | 2018-01-17 | — |
| IPR2017-01592 | 8410131 | IPR | Breckenridge Pharmaceutial, Inc. | Terminated-Settled | 2017-06-12 | — |
| IPR2017-01078 | 9006224 | IPR | West-Ward Pharmaceuticals International Limited | Terminated-Settled | 2017-03-13 | — |
| IPR2016-01479 | 9006224 | IPR | Par Pharmaceutical, Inc. et al. | Final Written Decision | 2016-07-22 | — |
| IPR2016-01461 | 9006224 | IPR | Roxane Laboratories, Inc. et al. | Institution Denied | 2016-07-19 | — |
| IPR2017-01063 | 9006224 | IPR | Argentum Pharmaceuticals LLC et al. | Final Written Decision | 2017-03-10 | — |
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Novartis Pharmaceuticals Corporation et al v. Par Pharmaceutical Inc. 3 patentseverolimus | D. Del. | 2015-01-23 | Terminated 2019-05-01 | — |
Novartis Pharmaceuticals Corporation et al v. Par Pharmaceutical Inc. 3 patentseverolimus | D. Del. | 2014-12-18 | Terminated 2019-05-01 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).